SUMMARY

Schistosomiasis is a neglected tropical disease caused by the helminth Schistosoma spp. and has the second highest global impact of all parasites. Schistosoma are transmitted through contact with contaminated fresh water predominantly in Africa, Asia, the Middle East, and South America. Due to the widespread prevalence of Schistosoma, co-infection with other infectious agents is common but often poorly described. Herein, we review recent literature describing the impact of Schistosoma co-infection between species and Schistosoma co-infection with blood-borne protozoa, soil-transmitted helminths, various intestinal protozoa, Mycobacterium, Salmonella, various urinary tract infection-causing agents, and viral pathogens. In each case, disease severity and, of particular interest, the immune landscape, are altered as a consequence of co-infection. Understanding the impact of schistosomiasis co-infections will be important when considering treatment strategies and vaccine development moving forward.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

3.
Colley DG, Bustinduy AL, Secor WE, King CH. 2014. Human schistosomiasis. Lancet 383:2253–2264.
4.
Pearce EJ, MacDonald AS. 2002. The immunobiology of schistosomiasis. Nat Rev Immunol 2:499–511.
5.
Martins Silva CL. 2016. Endothelial cells as targets of the intravascular parasitic disease schistosomiasis. Vascular Responses to Pathogens:195–207.
6.
Abdel Aziz N, Musaigwa F, Mosala P, Berkiks I, Brombacher F. 2022. Type 2 immunity: a two-edged sword in schistosomiasis immunopathology. Trends Immunol 43:657–673.
7.
Abruzzi A, Fried B. 2011. Coinfection of Schistosoma (Trematoda) with bacteria, protozoa and helminths. Adv Parasitol 77:1–85.
9.
Aula OP, McManus DP, Jones MK, Gordon CA. 2021. Schistosomiasis with a focus on Africa. Trop Med Infect Dis 6:109.
10.
van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, Habbema JDF, Engels D. 2003. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 86:125–139.
11.
Thomas CM, Timson DJ. 2020. The mechanism of action of praziquantel: can new drugs exploit similar mechanisms? Curr Med Chem 27:676–696.
12.
Kura K, Ayabina D, Hollingsworth TD, Anderson RM. 2022. Determining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni. Parasit Vectors 15:55.
13.
Toor J, Alsallaq R, Truscott JE, Turner HC, Werkman M, Gurarie D, King CH, Anderson RM. 2018. Are we on our way to achieving the 2020 goals for schistosomiasis morbidity control using current world health organization guidelines Clin Infect Dis 66:S245–S252.
14.
King CH. 2015. It’s time to dispel the myth of “asymptomatic” schistosomiasis. PLoS Negl Trop Dis 9:e0003504.
15.
Eveland LK, Morse SI. 1978. Schistosoma mansoni: infectivity and immunizing effects of in vitro derived schistosomula attenuated by X irradiation. Exp Parasitol 45:19–25.
16.
Minard P, Dean DA, Jacobson RH, Vannier WE, Murrell KD. 1978. Immunization of mice with cobalt-60 irradiated Schistosoma Mansoni cercariae. Am J Trop Med Hyg 27:76–86.
17.
Perera D. J., Ndao M. 2021. Promising technologies in the field of helminth vaccines. Front Immunol 12:711650.
18.
Perera DJ, Hassan AS, Jia Y, Ricciardi A, McCluskie MJ, Weeratna RD, Ndao M. 2020. Adjuvanted Schistosoma mansoni-cathepsin B With sulfated lactosyl archaeol archaeosomes or AddaVaxTM provides protection in a pre-clinical schistosomiasis Model. Front Immunol 11:605288.
19.
Perera DJ, Hassan AS, Liu SS, Elahi SM, Gadoury C, Weeratna RD, Gilbert R, Ndao M. 2022. A low dose adenovirus vectored vaccine expressing Schistosoma mansoni cathepsin B protects from intestinal schistosomiasis in mice. EBioMedicine 80:104036.
20.
Molehin AJ. 2020. Schistosomiasis vaccine development: update on human clinical trials. J Biomed Sci 27:28.
21.
Gryseels B, Polman K, Clerinx J, Kestens L. 2006. Human schistosomiasis. Lancet 368:1106–1118.
22.
De Clercq D, Vercruysse J, Picquet M, Shaw DJ, Diop M, Ly A, Gryseels B. 1999. The epidemiology of a recent focus of mixed Schistosoma haematobium and Schistosoma mansoni infections around the ‘Lac de Guiers’ in the Senegal River Basin, Senegal. Trop Med Int Health 4:544–550.
23.
Cunin P, Tchuem Tchuenté LA, Poste B, Djibrilla K, Martin PMV. 2003. Interactions between Schistosoma haematobium and Schistosoma mansoni in humans in north Cameroon. Trop Med Int Health 8:1110–1117.
24.
De Leo GA, Stensgaard A-S, Sokolow SH, N’Goran EK, Chamberlin AJ, Yang G-J, Utzinger J. 2020. Schistosomiasis and climate change. BMJ 371:m4324.
25.
Picquet M, Ernould JC, Vercruysse J, Southgate VR, Mbaye A, Sambou B, Niang M, Rollinson D. 1996. The epidemiology of human schistosomiasis in the Senegal river Basin. Transactions of the Royal Society of Tropical Medicine and Hygiene 90:340–346.
26.
Chaine JP, Malek EA. 1983. Urinary schistosomiasis in the sahelian region of the Senegal river basin. Trop Geogr Med 35:249–256.
27.
Talla I, Kongs A, Verlé P, Belot J, Sarr S, Coll AM. 1990. Outbreak of intestinal schistosomiasis in the Senegal River Basin. Ann Soc Belg Med Trop 70:173–180.
28.
Talla I, Kongs A, Verlé P. 1992. Preliminary study of the prevalence of human schistosomiasis in Richard-Toll (the Senegal river basin). Trans R Soc Trop Med Hyg 86:182.
29.
Boissier J, Grech-Angelini S, Webster BL, Allienne J-F, Huyse T, Mas-Coma S, Toulza E, Barré-Cardi H, Rollinson D, Kincaid-Smith J, Oleaga A, Galinier R, Foata J, Rognon A, Berry A, Mouahid G, Henneron R, Moné H, Noel H, Mitta G. 2016. Outbreak of urogenital schistosomiasis in Corsica (France): an epidemiological case study. Lancet Infect Dis 16:971–979.
30.
Rothe C, Zimmer T, Schunk M, Wallrauch C, Helfrich K, Gültekin F, Bretzel G, Allienne J-F, Boissier J. 2021. Developing endemicity of schistosomiasis, Corsica, France. Emerg Infect Dis 27:319–321.
31.
Wellinghausen N, Moné H, Mouahid G, Nebel A, Tappe D, Gabriel M. 2022. A family cluster of schistosomiasis acquired in Solenzara River, Corsica (France) — Solenzara River is clearly a transmission site for schistosomiasis in Corsica. Parasitol Res 121:2449–2452.
32.
Léger E, Borlase A, Fall CB, Diouf ND, Diop SD, Yasenev L, Catalano S, Thiam CT, Ndiaye A, Emery A, Morrell A, Rabone M, Ndao M, Faye B, Rollinson D, Rudge JW, Sène M, Webster JP. 2020. Prevalence and distribution of schistosomiasis in human, livestock, and snail populations in northern Senegal: a One Health epidemiological study of a multi-host system. Lancet Planet Health 4:e330–e342.
33.
Stensgaard AS, Vounatsou P, Sengupta ME, Utzinger J. 2019. Schistosomes, snails and climate change: current trends and future expectations. Acta Trop 190:257–268.
34.
Geiger SM. 2008. Immuno-epidemiology of Schistosoma mansoni infections in endemic populations co-infected with soil-transmitted helminths: present knowledge, challenges, and the need for further studies. Acta Trop 108:118–123.
35.
Phillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis WC, Wells TNC. 2017. Malaria. Nat Rev Dis Primers 3:17050.
36.
Patel P, Rose CE, Kjetland EF, Downs JA, Mbabazi PS, Sabin K, Chege W, Watts DH, Secor WE. 2021. Association of schistosomiasis and HIV infections: a systematic review and meta-analysis. Int J Infect Dis 102:544–553.
37.
Baya B, Kone B, Somboro A, Kodio O, Somboro AM, Diarra B, Traore FG, Kone D, Traore MA, Kone M, Togo AG, Sarro YS, Maiga A, Maiga M, Toloba Y, Diallo S, Murphy RL, Doumbia S. 2023. Prevalence and clinical relevance of Schistosoma mansoni co-infection with Mycobacterium tuberculosis: a systematic literature review. Open J Epidemiol 13:97–111.
38.
Petrellis G, Piedfort O, Katsandegwaza B, Dewals BG. 2023. Parasitic worms affect virus coinfection: a mechanistic overview. Trends Parasitol 39:358–372.
39.
Rovira-Diaz E, El-Naccache DW, Reyes J, Zhao Y, Nasuhidehnavi A, Chen F, Gause WC, Yap GS. 2022. The impact of helminth coinfection on innate and adaptive immune resistance and disease tolerance during toxoplasmosis. J Immunol 209:2160–2171.
40.
Desai P, Diamond MS, Thackray LB. 2021. Helminth-virus interactions: determinants of coinfection outcomes. Gut Microbes 13:1961202.
41.
Winkel BMF, Dalenberg MR, de Korne CM, Feijt C, Langenberg MCC, Pelgrom L, Ganesh MS, Yazdanbakhsh M, Smits HH, de Jong EC, Everts B, van Leeuwen FWB, Hokke CH, Roestenberg M. 2018. Early induction of human regulatory dermal antigen presenting cells by skin-penetrating Schistosoma mansoni cercariae. Front Immunol 9:2510.
42.
de Jesus AR, Silva A, Santana LB, Magalhães A, de Jesus AA, de Almeida RP, Rêgo MAV, Burattini MN, Pearce EJ, Carvalho EM. 2002. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis 185:98–105.
43.
Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. 2007. Katayama syndrome. Lancet Infect Dis 7:218–224.
44.
Schwartz E, Rozenman J, Perelman M. 2000. Pulmonary manifestations of early schistosome infection among nonimmune travelers. Am J Med 109:718–722.
45.
Pearce EJ, M Kane C, Sun J, J Taylor J, McKee AS, Cervi L. 2004. Th2 response polarization during infection with die helminth parasite Schistosoma mansoni. Immunol Rev 201:117–126.
46.
Brunet LR, Finkelman FD, Cheever AW, Kopf MA, Pearce EJ. 1997. IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis. J Immunol 159:777–785.
47.
Schwartz C, Fallon PG. 2018. Schistosoma “eggs-iting” the host: granuloma formation and egg excretion. Front Immunol 9:2492.
48.
Tawiah D. 2014. Female genital schistosomiasis, genital tract infections and HIV co-infection in the Volta Basin of Ghana. IJTDH 3:94–103.
49.
Feldmeier H, Krantz I, Poggensee G. 1994. Female genital schistosomiasis as a risk-factor for the transmission of HIV. Int J STD AIDS 5:368–372.
50.
Sturt AS, Webb EL, Francis SC, Hayes RJ, Bustinduy AL. 2020. Beyond the barrier: female genital schistosomiasis as a potential risk factor for HIV-1 acquisition. Acta Trop 209:105524.
51.
Kjetland EF, Ndhlovu PD, Mduluza T, Deschoolmeester V, Midzi N, Gomo E, Gwanzura L, Mason PR, Vermorken JB, Friis H, Gundersen SG, Baay MFD. 2010. The effects of genital Schistosoma haematobium on human papillomavirus and the development of cervical neoplasia after five years in a Zimbabwean population. Eur J Gynaecol Oncol 31:169–173.
52.
Mohammed SA, Hetta HF, Zahran AM, Tolba MEM, Attia RAH, Behnsawy HM, Algammal AM, Batiha G-S, Mohammed AQ, Ahmad AA. 2023. T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine profile in Schistosoma haematobium associated bladder cancer: first report from Upper Egypt. PLoS Negl Trop Dis 17:e0011258.
53.
Meurs L, Mbow M, Vereecken K, Menten J, Mboup S, Polman K. 2012. Epidemiology of mixed Schistosoma mansoni and Schistosoma haematobium infections in northern Senegal. Int J Parasitol 42:305–311.
54.
Webster BL, Diaw OT, Seye MM, Faye DS, Stothard JR, Sousa-Figueiredo JC, Rollinson D. 2013. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns. Acta Trop 128:292–302.
55.
Knowles SCL, Webster BL, Garba A, Sacko M, Diaw OT, Fenwick A, Rollinson D, Webster JP. 2015. Epidemiological interactions between urogenital and intestinal human schistosomiasis in the context of praziquantel treatment across three West African countries. PLoS Negl Trop Dis 9:e0004019.
56.
Meurs L, Mbow M, Boon N, Vereecken K, Amoah AS, Labuda LA, Dièye TN, Mboup S, Yazdanbakhsh M, Polman K. 2014. Cytokine responses to Schistosoma mansoni and Schistosoma haematobium in relation to infection in a co-endemic focus in northern Senegal. PLoS Negl Trop Dis 8:e3080.
57.
Meurs L, Mbow M, Boon N, van den Broeck F, Vereecken K, Dièye TN, Abatih E, Huyse T, Mboup S, Polman K. 2013. Micro-geographical heterogeneity in Schistosoma mansoni and S. haematobium infection and morbidity in a co-endemic community in northern Senegal. PLoS Negl Trop Dis 7:e2608.
58.
Meurs L, Mbow M, Vereecken K, Menten J, Mboup S, Polman K. 2012. Bladder morbidity and hepatic fibrosis in mixed Schistosoma haematobium and S. mansoni infections: a population-wide study in Northern Senegal. PLoS Negl Trop Dis 6:e1829.
59.
Cunin P, Griffet A, Poste B, Djibrilla K, Martin PMV. 2000. Epidemic Schistosoma mansoni in a known S. haematobium area. Trans R Soc Trop Med Hyg 94:657–660.
60.
Ugbomoiko US, Dalumo V, Danladi YK, Heukelbach J, Ofoezie IE. 2012. Concurrent urinary and intestinal schistosomiasis and intestinal helminthic infections in schoolchildren in Ilobu, South-western Nigeria. Acta Trop 123:16–21.
61.
Anyan WK, Abonie SD, Aboagye-Antwi F, Tettey MD, Nartey LK, Hanington PC, Anang AK, Muench SB. 2019. Concurrent Schistosoma mansoni and Schistosoma haematobium infections in a peri-urban community along the Weija dam in Ghana: a wake up call for effective National Control Programme. Acta Trop 199:105116.
62.
Gouvras AN, Kariuki C, Koukounari A, Norton AJ, Lange CN, Ireri E, Fenwick A, Mkoji GM, Webster JP. 2013. The impact of single versus mixed Schistosoma haematobium and S. mansoni infections on morbidity profiles amongst school-children in Taveta, Kenya. Acta Trop 128:309–317.
63.
Koukounari A, Donnelly CA, Sacko M, Keita AD, Landouré A, Dembelé R, Bosqué-Oliva E, Gabrielli AF, Gouvras A, Traoré M, Fenwick A, Webster JP. 2010. The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment. BMC Infect Dis 10:227.
64.
Fall CB, Lambert S, Léger E, Yasenev L, Garba AD, Diop SD, Borlase A, Catalano S, Faye B, Walker M, Sene M, Webster JP. 2021. Hybridized zoonotic Schistosoma infections result in hybridized morbidity profiles: a clinical morbidity study amongst co-infected human populations of Senegal. Microorganisms 9:1776.
65.
Webster BL, Southgate VR, Tchuem Tchuenté LA. 1999. Mating interactions between Schistosoma haematobium and S. mansoni. J Helminthol 73:351–356.
66.
Brumpt E. 1930. Localisation vésicale expérimentale d’œufs de Schistosoma mansoni chez une souris. Localisations vésicales à S. mansoni et rectales à S. haematobium chez l’homme. Ann Parasitol Hum Comp 8:298–308.
67.
Barsoum RS, Esmat G, El-Baz T. 2013. Human schistosomiasis: clinical perspective: review. J Adv Res 4:433–444.
68.
Garba A, Lamine MS, Barkiré N, Djibo A, Sofo B, Gouvras AN, Labbo R, Sebangou H, Webster JP, Fenwick A, Utzinger J. 2013. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop 128:334–344.
69.
Tchuem Tchuenté L-A, Momo SC, Stothard JR, Rollinson D. 2013. Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenital schistosomiasis in Cameroon. Acta Trop 128:275–283.
70.
Odegaard JI, Hsieh MH. 2014. Immune responses to Schistosoma haematobium infection. Parasite Immunol 36:428–438.
71.
Panzner U, Boissier J. 2021. Natural intra- and interclade human hybrid schistosomes in Africa with considerations on prevention through vaccination. Microorganisms 9:1465.
72.
Leger E, Webster JP. 2017. Hybridizations within the Genus Schistosoma: implications for evolution, epidemiology and control. Parasitology 144:65–80.
73.
King KC, Stelkens RB, Webster JP, Smith DF, Brockhurst MA. 2015. Hybridization in parasites: consequences for adaptive evolution, pathogenesis, and public health in a changing world. PLoS Pathog 11:e1005098.
74.
Depaquit J, Akhoundi M, Haouchine D, Mantelet S, Izri A. 2019. No limit in interspecific hybridization in schistosomes: observation from a case report. Parasite 26:10.
75.
Le Govic Y, Kincaid-Smith J, Allienne J-F, Rey O, de Gentile L, Boissier J. 2019. Schistosoma haematobium–Schistosoma mansoni hybrid parasite in migrant boy. Emerg Infect Dis 25:365–367.
76.
Huyse T, Van den Broeck F, Hellemans B, Volckaert FAM, Polman K. 2013. Hybridisation between the two major African schistosome species of humans. Int J Parasitol 43:687–689.
78.
Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG. 2018. Soil-transmitted helminth infections. Lancet 391:252–265.
79.
Vacca F, Le Gros G. 2022. Tissue-specific immunity in helminth infections. Mucosal Immunol 15:1212–1223.
80.
Maizels RM, Hewitson JP, Smith KA. 2012. Susceptibility and immunity to helminth parasites. Curr Opin Immunol 24:459–466.
81.
McSorley HJ, Maizels RM. 2012. Helminth infections and host immune regulation. Clin Microbiol Rev 25:585–608.
82.
Yajima A, Gabrielli AF, Montresor A, Engels D. 2011. Moderate and high endemicity of schistosomiasis is a predictor of the endemicity of soil-transmitted helminthiasis - systematic review. Trans R Soc Trop Med Hyg 105:68–73.
83.
Schistosomiasis and soil transmitted helminthiases: progress report, 2021 – Schistosomiase et Géohelminthiases: rapport de situation. 2021. Weekly Epidemiological Record = Relevé Épidémiologique Hebdomadaire 97, 621–631.
84.
Babu S, Nutman TB. 2019. 31 - immune responses to helminth infection, p 437–447. In Clinical immunology: principles and practice
85.
de Rezende MC, Araújo ES, Moreira JMP, Rodrigues VF, Rodrigues JL, Pereira C de J, Negrão-Corrêa D. 2015. Effect of different stages of Schistosoma mansoni infection on the parasite burden and immune response to Strongyloides venezuelensis in co-infected mice. Parasitol Res 114:4601–4616.
86.
de Rezende MC, Moreira JMP, Fernandes LLM, Rodrigues VF, Negrão-Corrêa D. 2020. Strongyloides venezuelensis-infection alters the profile of cytokines and liver inflammation in mice co-infected with Schistosoma mansoni. Cytokine 127:154931.
87.
Bazzone LE, Smith PM, Rutitzky LI, Shainheit MG, Urban JF, Setiawan T, Blum AM, Weinstock JV, Stadecker MJ. 2008. Coinfection with the intestinal nematode Heligmosomoides polygyrus markedly reduces hepatic egg-induced immunopathology and proinflammatory cytokines in mouse models of severe schistosomiasis. Infect Immun 76:5164–5172.
88.
Bickle QD, Solum J, Helmby H. 2008. Chronic intestinal nematode infection exacerbates experimental Schistosoma mansoni infection. Infect Immun 76:5802–5809.
89.
Le L, Khatoon S, Jiménez P, Peterson C, Kernen R, Zhang W, Molehin AJ, Lazarus S, Sudduth J, May J, Karmakar S, Rojo JU, Ahmad G, Torben W, Carey D, Wolf RF, Papin JF, Siddiqui AA. 2020. Chronic whipworm infection exacerbates Schistosoma mansoni egg-induced hepatopathology in non-human primates. Parasit Vectors 13:109.
90.
Geiger SM, Alexander NDE, Fujiwara RT, Brooker S, Cundill B, Diemert DJ, Correa-Oliveira R, Bethony JM. 2011. Necator americanus and helminth co-infections: further down-modulation of hookworm-specific type 1 immune responses. PLoS Negl Trop Dis 5:e1280.
91.
Adewale B, Heintz JR, Pastore CF, Rossi HL, Hung L-Y, Rahman N, Bethony J, Diemert D, Babatunde JA, Herbert DR. 2021. Parasitic helminth infections in humans modulate Trefoil Factor levels in a manner dependent on the species of parasite and age of the host. PLoS Negl Trop Dis 15:e0009550.
92.
Pinot de Moira A, Jones FM, Wilson S, Tukahebwa E, Fitzsimmons CM, Mwatha JK, Bethony JM, Kabatereine NB, Dunne DW, Urban JF. 2013. Effects of treatment on IgE responses against parasite allergen-like proteins and immunity to reinfection in childhood schistosome and hookworm coinfections. Infect Immun 81:23–32.
93.
Pinot de Moira A, Fitzsimmons CM, Jones FM, Wilson S, Cahen P, Tukahebwa E, Mpairwe H, Mwatha JK, Bethony JM, Skov PS, Kabatereine NB, Dunne DW. 2014. Suppression of basophil histamine release and other IgE-dependent responses in childhood Schistosoma mansoni/hookworm coinfection. J Infect Dis 210:1198–1206.
94.
Campolina SS, Araujo MSS, Rezende T, Matoso L, Quites HFO, Teixeira-Carvalho A, Martins-Filho OA, Gazzinelli A, Correa-Oliveira R. 2015. Effective anthelmintic therapy of residents living in endemic area of high prevalence for Hookworm and Schistosoma mansoni infections enhances the levels of allergy risk factor anti-Der p1 IgE. Results Immunol 5:6–12.
96.
Parums DV. 2023. Editorial: current status of two adjuvanted malaria vaccines and the world health organization (WHO) strategy to eradicate malaria by 2030. Med Sci Monit 29:e939357.
97.
López C, Yepes-Pérez Y, Hincapié-Escobar N, Díaz-Arévalo D, Patarroyo MA. 2017. What is known about the immune response induced by Plasmodium vivax malaria vaccine candidates?. Front Immunol 8:126.
98.
CDC - Schistosomiasis - Epidemiology & Risk Factors. https://www.cdc.gov/parasites/schistosomiasis/epi.html.
99.
Degarege A, Degarege D, Veledar E, Erko B, Nacher M, Beck-Sague CM, Madhivanan P. 2016. Plasmodium falciparum infection status among children with Schistosoma in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Negl Trop Dis 10:e0005193.
100.
Hailu T, Yimer M, Mulu W, Abera B. 2018. Synergetic effects of Plasmodium, hookworm, and Schistosoma mansoni infections on hemoglobin level among febrile school age children in Jawe Worda, Northwest Ethiopia. J Parasitol Res 2018:9573413.
101.
Orish VN, Ofori-Amoah J, Amegan-Aho KH, Osei-Yeboah J, Lokpo SY, Osisiogu EU, Agordoh PD, Adzaku FK. 2019. Prevalence of polyparasitic infection among primary school children in the volta region of Ghana. Open Forum Infect Dis 6:ofz153.
102.
Sumbele IUN, Otia OV, Bopda OSM, Ebai CB, Kimbi HK, Nkuo-Akenji T. 2021. Polyparasitism with Schistosoma haematobium, Plasmodium and soil-transmitted helminths in school-aged children in Muyuka-Cameroon following implementation of control measures: a cross sectional study. Infect Dis Poverty 10:14.
103.
Anchang-Kimbi JK, Elad DM, Sotoing GT, Achidi EA. 2017. Coinfection with Schistosoma haematobium and Plasmodium falciparum and anaemia severity among pregnant women in Munyenge, mount cameroon area: a cross-sectional study. J Parasitol Res 2017:6173465.
104.
McDowell D, Hurt L, Kabatereine NB, Stothard JR, Lello J. 2022. Infection history and current coinfection with Schistosoma mansoni decreases Plasmodium species intensities in preschool children in Uganda. J Infect Dis 225:2181–2186.
105.
Tuasha N, Hailemeskel E, Erko B, Petros B. 2019. Comorbidity of intestinal helminthiases among malaria outpatients of Wondo Genet health centers, southern Ethiopia: implications for integrated control. BMC Infect Dis 19:659.
106.
Nyarko R, Torpey K, Ankomah A. 2018. Schistosoma haematobium, Plasmodium falciparum infection and anaemia in children in Accra, Ghana. Trop Dis Travel Med Vaccines 4:3.
107.
Dassah S, Asiamah GK, Harun V, Appiah-Kubi K, Oduro A, Asoala V, Amenga-Etego L. 2022. Urogenital schistosomiasis transmission, malaria and anemia among school-age children in Northern Ghana. Heliyon 8:e10440.
108.
Morenikeji OA, Eleng IE, Atanda OS, Oyeyemi OT. 2016. Renal related disorders in concomitant Schistosoma haematobium-Plasmodium falciparum infection among children in a rural community of Nigeria. J Infect Public Health 9:136–142.
109.
Santano R, Rubio R, Grau-Pujol B, Escola V, Muchisse O, Cuamba I, Vidal M, Cisteró P, Ruiz-Olalla G, Aguilar R, et al. 2021. Plasmodium falciparum and helminth coinfections increase IGE and parasite-specific IgG responses. Microbiol Spectr 9:e0110921.
110.
Tokplonou L, Nouatin O, Sonon P, M’po G, Glitho S, Agniwo P, Gonzalez-Ortiz D, Tchégninougbo T, Ayitchédji A, Favier B, Donadi EA, Milet J, Luty AJF, Massougbodji A, Garcia A, Ibikounlé M, Courtin D. 2020. Schistosoma haematobium infection modulates Plasmodium falciparum parasite density and antimalarial antibody responses. Parasite Immunol 42:e12702.
111.
Lyke KE, Dabo A, Arama C, Diarra I, Plowe CV, Doumbo OK, Sztein MB. 2017. Long-term maintenance of CD4 T cell memory responses to malaria antigens in Malian children coinfected with Schistosoma haematobium. Front Immunol 8:1995.
112.
Nyakundi RK, Nyamongo O, Maamun J, Akinyi M, Mulei I, Farah IO, Blankenship D, Grimberg B, Hau J, Malhotra I, Ozwara H, King CL, Kariuki TM. 2016. Protective effect of chronic schistosomiasis in baboons coinfected with Schistosoma mansoni and Plasmodium knowlesi. Infect Immun 84:1320–1330.
113.
Nyakundi RK, Hau J, Ogongo P, Nyamongo O, Jeneby M, Akinyi M, Mulei I, Nyundo F, Farah I, Malhotra I, Ozwara H, King CL, Kariuki T. 2022. Acquired clinical immunity to malaria in nonhuman primates coinfected with Schistosoma and Plasmodium parasites. Infect Immun 90:e0046421.
114.
Wang M, Feng Y, Pang W, Qi Z, Zhang Y, Guo Y, Luo E, Cao Y. 2014. Parasite densities modulate susceptibility of mice to cerebral malaria during co-infection with Schistosoma japonicum and Plasmodium berghei. Malar J 13:116.
115.
Moriyasu T, Nakamura R, Deloer S, Senba M, Kubo M, Inoue M, Culleton R, Hamano S. 2018. Schistosoma mansoni infection suppresses the growth of Plasmodium yoelii parasites in the liver and reduces gametocyte infectivity to mosquitoes. PLoS Negl Trop Dis 12:e0006197.
116.
Abay SM, Tilahun M, Fikrie N, Habtewold A. 2013. Plasmodium falciparum and Schistosoma mansoni coinfection and the side benefit of artemether-lumefantrine in malaria patients. J Infect Dev Ctries 7:468–474.
117.
Mbanzulu KM, Zanga JK, Mukendi JPK, Mbaya Ntita F, Matangila JR, Muhindo HM, Mpoyi Wa Mpoyi S, Aloni MN, Wumba R. 2018. The impact of artesunate-amodiaquine on Schistosoma mansoni infection among children infected by Plasmodium in rural area of lemfu, kongo central, democratic Republic of the Congo. Biomed Res Int 2018:3487183.
118.
Pishchany G, Skaar EP. 2012. Taste for blood: hemoglobin as a nutrient source for pathogens. PLoS Pathog 8:e1002535.
119.
Figueiredo B-P, Ricci ND, de Assis NRG, de Morais SB, Fonseca CT, Oliveira SC. 2015. Kicking in the guts: Schistosoma mansoni digestive tract proteins are potential candidates for vaccine development. Front Immunol 6:22.
120.
Coronado LM, Montealegre S, Chaverra Z, Mojica L, Espinosa C, Almanza A, Correa R, Stoute JA, Gittens RA, Spadafora C. 2016. Blood stage Plasmodium falciparum exhibits biological responses to direct current electric fields. PLoS One 11:e0161207.
121.
Huang H-H, Rigouin C, Williams DL. 2012. The redox biology of schistosome parasites and applications for drug development. Curr Pharm Des 18:3595–3611.
122.
Burza S, Croft SL, Boelaert M. 2018. Leishmaniasis. Lancet 392:951–970.
123.
Lypaczewski P, Matlashewski G. 2021. Leishmania donovani hybridisation and introgression in nature: a comparative genomic investigation. Lancet Microbe 2:e250–e258.
124.
Volpedo G, Huston RH, Holcomb EA, Pacheco-Fernandez T, Gannavaram S, Bhattacharya P, Nakhasi HL, Satoskar AR. 2021. From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection. Expert Rev Vaccines 20:1431–1446.
125.
Paulini K, Lypaczewski P, Zhang W-W, Perera DJ, Ndao M, Matlashewski G. 2022. Investigating the Leishmania donovani sacp gene and its role in macrophage infection and survival in mice. Trop Med Infect Dis 7:384.
126.
Prevention C.-C. for D. C. and. CDC - Leishmaniasis - Biology. (2020).
127.
Miranda GS, Resende SD, Cardoso DT, Camelo GMA, Silva J, de Castro VN, Geiger SM, Carneiro M, Negrão-Corrêa D. 2021. Previous history of American tegumentary leishmaniasis alters susceptibility and immune response against Schistosoma mansoni infection in humans. Front Immunol 12:630934.
128.
Carstens-Kass J, Paulini K, Lypaczewski P, Matlashewski G. 2021. A review of the leishmanin skin test: a neglected test for a neglected disease. PLoS Negl Trop Dis 15:e0009531.
129.
O’Neal SE, Guimarães LH, Machado PR, Alcântara L, Morgan DJ, Passos S, Glesby MJ, Carvalho EM. 2007. Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis 195:142–148.
130.
Fitzsimmons CM, Falcone FH, Dunne DW. 2014. Helminth allergens, parasite-specific IgE, and its protective role in human immunity. Front Immunol 5:61.
131.
Geiger SM, Jardim-Botelho A, Williams W, Alexander N, Diemert DJ, Bethony JM. 2013. Serum CCL11 (eotaxin-1) and CCL17 (TARC) are serological indicators of multiple helminth infections and are driven by Schistosoma mansoni infection in humans. Trop Med Int Health 18:750–760.
132.
Cota GF, Gomes LI, Pinto BF, Santos-Oliveira JR, Da-Cruz AM, Pedrosa MS, Tafuri WL, Rabello A. 2012. Dyarrheal syndrome in a patient co-infected with Leishmania Infantum and Schistosoma mansoni. Case Rep Med 2012:240512.
133.
Gregorio AW, Vasconcellos MRA, Enokihara M, Guerra JM, Nonogaki S, Tomimori J. 2019. Cutaneous schistosomiasis and leishmaniasis coinfection: a case report. J Eur Acad Dermatol Venereol 33:1781–1783.
134.
La Flamme AC, Scott P, Pearce EJ. 2002. Schistosomiasis delays lesion resolution during Leishmania major infection by impairing parasite killing by macrophages. Parasite Immunol 24:339–345.
135.
Hassan MF, Zhang Y, Engwerda CR, Kaye PM, Sharp H, Bickle QD. 2006. The Schistosoma mansoni hepatic egg granuloma provides a favorable microenvironment for sustained growth of Leishmania donovani. Am J Pathol 169:943–953.
136.
Khayeka-Wandabwa C, Kutima H, Nyambati VCS, Ingonga J, Oyoo-Okoth E, Karani L, Jumba B, Githuku K, Anjili CO. 2013. Combination therapy using Pentostam and Praziquantel improves lesion healing and parasite resolution in BALB/c mice co-infected with Leishmania major and Schistosoma mansoni. Parasit Vectors 6:244.
137.
Camelo GMA, Silva J de O, Geiger SM, Melo MN, Negrão-Corrêa DA. 2023. Schistosoma and Leishmania: an untold story of coinfection. TropicalMed 8:383.
139.
Franco JR, Cecchi G, Paone M, Diarra A, Grout L, Kadima Ebeja A, Simarro PP, Zhao W, Argaw D. 2022. The elimination of human African trypanosomiasis: achievements in relation to WHO road map targets for 2020. PLoS Negl Trop Dis 16:e0010047.
140.
Auty H, Morrison LJ, Torr SJ, Lord J. 2016. Transmission dynamics of rhodesian sleeping sickness at the interface of wildlife and livestock areas. Trends Parasitol 32:608–621.
142.
Chagas disease - PAHO/WHO | Pan American Health Organization. https://www.paho.org/en/topics/chagas-disease.
143.
Simarro PP, Cecchi G, Franco JR, Paone M, Diarra A, Ruiz-Postigo JA, Fèvre EM, Mattioli RC, Jannin JG. 2012. Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis 6:e1859.
144.
Kloetzel K, Faleiros JJ, Mendes SR, Stanley CT, Sanches Arias H. 1973. Concomitant infection of albino mice by Trypanosoma cruzi and Schistosoma mansoni. Parasitological parameters. Trans R Soc Trop Med Hyg 67:652–658.
145.
Rodrigues JPF, Caldas IS, Gonçalves RV, Almeida LA, Souza RLM, Novaes RD. 2017. S. mansoni-T. cruzi co-infection modulates arginase-1/iNOS expression, liver and heart disease in mice. Nitric Oxide 66:43–52.
146.
Hams E, Aviello G, Fallon PG. 2013. The Schistosoma granuloma: friend or foe?. Front Immunol 4:89.
147.
Dunne DW, Lucas S, Bickle Q, Pearson S, Madgwick L, Bain J, Doenhoff MJ. 1981. Identification and partial purification of an antigen (ω1) from Schistosoma mansoni eggs which is putatively hepatotoxic in T-cell deprived mice. Trans R Soc Trop Med Hyg 75:54–71.
148.
Fagbemi BO. 1987. Interference with homologous immunity and faecal egg excretion in Schistosoma infections in mice concurrently infected with Trypanosoma brucei and Schistosoma mansoni. Folia Parasitol (Praha) 34:317–322.
149.
Fagbemi BO, Christensen NO, Dipeolu OO. 1987. Effects of Trypanosoma brucei and Babesia microti infections on the primary granulomatous reaction to Schistosoma eggs in mice. Lab Anim 21:121–124.
150.
Genaro O, Brener Z, Coelho PM. 1986. Schistosoma mansoni: immunodepression of hepatic schistosome granuloma formation in mice infected by Trypanosoma cruzi. Rev Soc Bras Med Trop 19:35–37.
151.
Prevention. 2019. C.-C. for D. C. and. CDC - Toxoplasmosis - Epidemiology & Risk Factors
152.
de-la-Torre A, Sauer A, Pfaff AW, Bourcier T, Brunet J, Speeg-Schatz C, Ballonzoli L, Villard O, Ajzenberg D, Sundar N, Grigg ME, Gomez-Marin JE, Candolfi E. 2013. Severe South American ocular toxoplasmosis is associated with decreased Ifn-γ/Il-17a and increased Il-6/Il-13 intraocular levels. PLoS Negl Trop Dis 7:e2541.
153.
Pernas L, Ramirez R, Holmes TH, Montoya JG, Boothroyd JC. 2014. Immune profiling of pregnant Toxoplasma-infected US and Colombia patients reveals surprising impacts of infection on peripheral blood cytokines. J Infect Dis 210:923–931.
154.
de la Mata Navazo S, Slöcker Barrio M, García-Morín M, Beléndez C, Escobar Fernández L, Rincón-López EM, Aguilera Alonso D, Guinea J, Marín M, Butragueño-Laiseca L, López-Herce Cid J. 2021. Case report: severe ARDS in a pediatric hematopoietic stem-cell transplantation recipient caused by disseminated toxoplasmosis. Front Pediatr 9:810718.
155.
Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet 363:1965–1976.
156.
Figueroa-Vercellino JP, Miguel L, Moll-Udina A, Alba-Linero C, Llorenç V, Adán A. 2021. Atypical toxoplasmic retinochoroiditis in patients with malignant hematological diseases. Arch Soc Esp Oftalmol (Engl Ed) 96:152–156.
157.
Dubey JP, Murata FHA, Cerqueira-Cézar CK, Kwok OCH, Villena I. 2021. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. Parasitology 148:1406–1416.
158.
Koblansky AA, Jankovic D, Oh H, Hieny S, Sungnak W, Mathur R, Hayden MS, Akira S, Sher A, Ghosh S. 2013. Recognition of profilin by Toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity 38:119–130.
159.
Plattner F, Yarovinsky F, Romero S, Didry D, Carlier M-F, Sher A, Soldati-Favre D. 2008. Toxoplasma profilin is essential for host cell invasion and TLR11-dependent induction of an interleukin-12 response. Cell Host Microbe 3:77–87.
160.
Johnson LL, Sayles PC. 2002. Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice. Infect Immun 70:185–191.
161.
Deshmukh AS, Gurupwar R, Mitra P, Aswale K, Shinde S, Chaudhari S. 2021. Toxoplasma gondii induces robust humoral immune response against cyst wall antigens in chronically infected animals and humans. Microb Pathog 152:104643.
162.
Suzuki Y, Orellana MA, Schreiber RD, Remington JS. 1988. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240:516–518.
163.
Bigna JJ, Tochie JN, Tounouga DN, Bekolo AO, Ymele NS, Youda EL, Sime PS, Nansseu JR. 2020. Global, regional, and country seroprevalence of Toxoplasma gondii in pregnant women: a systematic review, modelling and meta-analysis. Sci Rep 10:12102.
164.
Khan MB, Sonaimuthu P, Lau YL, Al-Mekhlafi HM, Mahmud R, Kavana N, Kassuku A, Kasanga C. 2014. High seroprevalence of echinococossis, schistosomiasis and toxoplasmosis among the populations in Babati and Monduli districts, Tanzania. Parasit Vectors 7:505.
165.
Felician EK, Ngoda OA, Jahanpour OF, Kahima J, Msuya SE, Lukambagire AH. 2022. Placental parasitic infections and pregnancy outcomes among women delivering at a tertiary hospital in northern Tanzania. East Afr Health Res J 6:141–146.
166.
Afifi MA, Tawfeek GM, Abdel Aziz SS, Abdel Aaty HA. 2000. Assessment of the role of soluble intracellular adhesion molecule-1 (sICAM-1) in the pathogenesis and as a marker of disease severity in different stages of human schistosomiasis and toxoplasmosis. J Egypt Soc Parasitol 30:537–545.
167.
Fayad ME, Farrag AM, Hussein MM, Amer NA. 1992. Studies on chronic liver diseases in patients with and without Toxoplasma latent infection. J Egypt Soc Parasitol 22:807–815.
168.
Liu X, Wu M, Liu Y, Li J, Yang D, Jiang L. 2021. Foodborne parasites dominate current parasitic infections in Hunan province, China. Front Cell Infect Microbiol 11:774980.
169.
Marshall AJ, Brunet LR, van Gessel Y, Alcaraz A, Bliss SK, Pearce EJ, Denkers EY. 1999. Toxoplasma gondii and Schistosoma mansoni synergize to promote hepatocyte dysfunction associated with high levels of plasma TNF-α and early death in C57Bl/6 mice. J Immunol 163:2089–2097.
170.
Kloetzel K, Chieffi PP, Faleiros JJ, Filho TJ. 1977. Mortality and other parameters of concomitant infections in albino mice: the Schistosoma-Toxoplasma model. Trop Geogr Med 29:407–410.
171.
Pêgo B, Martinusso CA, Bernardazzi C, Ribeiro BE, de Araujo Cunha AF, de Souza Mesquita J, Nanini HF, Machado MP, Castelo-Branco MTL, Cavalcanti MG, de Souza HSP. 2019. Schistosoma mansoni coinfection attenuates murine Toxoplasma gondii-induced Crohn’s-like Ileitis by preserving the epithelial barrier and downregulating the inflammatory response. Front Immunol 10:442.
172.
Araujo MI, Bliss SK, Suzuki Y, Alcaraz A, Denkers EY, Pearce EJ. 2001. Interleukin-12 promotes pathologic liver changes and death in mice coinfected with Schistosoma mansoni and Toxoplasma gondii. Infect Immun 69:1454–1462.
173.
Davis AN, Haque R, Petri WA. 2002. Update on protozoan parasites of the intestine. Curr Opin Gastroenterol 18:10–14.
174.
Berhe B, Bugssa G, Bayisa S, Alemu M. 2018. Foodborne intestinal protozoan infection and associated factors among patients with watery diarrhea in Northern Ethiopia; a cross-sectional study. J Health Popul Nutr 37:5.
175.
Fitri LE, Candradikusuma D, Setia YD, Wibawa PA, Iskandar A, Winaris N, Pawestri AR. 2022. Diagnostic methods of common intestinal protozoa: current and future immunological and molecular methods. Trop Med Infect Dis 7:253.
179.
Ahmadpour E, Safarpour H, Xiao L, Zarean M, Hatam-Nahavandi K, Barac A, Picot S, Rahimi MT, Rubino S, Mahami-Oskouei M, Spotin A, Nami S, Baghi HB. 2020. Cryptosporidiosis in HIV-positive patients and related risk factors: a systematic review and meta-analysis. Parasite 27:27.
180.
Squire SA, Ryan U. 2017. Cryptosporidium and Giardia in Africa: current and future challenges. Parasit Vectors 10:195.
181.
Kantor M, Abrantes A, Estevez A, Schiller A, Torrent J, Gascon J, Hernandez R, Ochner C. 2018. Entamoeba histolytica: updates in clinical manifestation, pathogenesis, and vaccine development. Can J Gastroenterol Hepatol 2018:4601420.
182.
Haque R, Huston CD, Hughes M, Houpt E, Petri WA. 2003. Amebiasis. N Engl J Med 348:1565–1573.
183.
Sardinha-Silva A, Alves-Ferreira EVC, Grigg ME. 2022. Intestinal immune responses to commensal and pathogenic protozoa. Front Immunol 13:963723.
184.
Gurung P, Kanneganti TD. 2016. Immune responses against protozoan parasites: a focus on the emerging role of Nod-like receptors. Cell Mol Life Sci 73:3035–3051.
185.
Nakada-Tsukui K, Nozaki T. 2016. Immune response of amebiasis and immune evasion by Entamoeba histolytica. Front Immunol 7:175.
186.
Lechner CJ, Komander K, Hegewald J, Huang X, Gantin RG, Soboslay PT, Agossou A, Banla M, Köhler C. 2013. Cytokine and chemokine responses to helminth and protozoan parasites and to fungus and mite allergens in neonates, children, adults, and the elderly. Immun Ageing 10:29.
187.
Hegewald J, Gantin RG, Lechner CJ, Huang X, Agosssou A, Agbeko YF, Soboslay PT, Köhler C. 2015. Cellular cytokine and chemokine responses to parasite antigens and fungus and mite allergens in children co-infected with helminthes and protozoa parasites. J Inflamm (Lond) 12:5.
188.
Al-Shehri H, Stanton MC, LaCourse JE, Atuhaire A, Arinaitwe M, Wamboko A, Adriko M, Kabatereine NB, Stothard JR. 2016. An extensive burden of giardiasis associated with intestinal schistosomiasis and anaemia in school children on the shoreline of Lake Albert, Uganda. Trans R Soc Trop Med Hyg 110:597–603.
189.
Weerakoon KG, Gordon CA, Williams GM, Cai P, Gobert GN, Olveda RM, Ross AG, Olveda DU, McManus DP. 2018. Co-parasitism of intestinal protozoa and Schistosoma japonicum in a rural community in the Philippines. Infect Dis Poverty 7:121.
190.
Ketema W, Taye K, Tagesse N, Shibeshi MS, Alemayehu B, G/Tsadik F, Girma B, Teklehaymanote A, Debiso A. 2022. Fulminant hepatitis and ulcerative colitis: case report of Ethiopian child with schistosomiasis and amebiasis co-infection. Int Med Case Rep J 15:409–418.
191.
Archer J, O’Halloran L, Al-Shehri H, Summers S, Bhattacharyya T, Kabaterine NB, Atuhaire A, Adriko M, Arianaitwe M, Stewart M, LaCourse EJ, Webster BL, Bustinduy AL, Stothard JR. 2020. Intestinal schistosomiasis and giardiasis co-infection in sub-Saharan Africa: can a one health approach improve control of each waterborne parasite simultaneously. Trop Med Infect Dis 5:137.
192.
McCreesh N, Mohlamonyane M, Edwards A, Olivier S, Dikgale K, Dayi N, Gareta D, Wood R, Grant AD, White RG, Middelkoop K. 2022. Improving estimates of social contact patterns for airborne transmission of respiratory pathogens. Emerg Infect Dis 28:2016–2026.
194.
Lin PL, Rutledge T, Green AM, Bigbee M, Fuhrman C, Klein E, Flynn JL. 2012. CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res Hum Retroviruses 28:1693–1702.
195.
Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178:2243–2247.
196.
Mhimbira F, Hella J, Said K, Kamwela L, Sasamalo M, Maroa T, Chiryamkubi M, Mhalu G, Schindler C, Reither K, Knopp S, Utzinger J, Gagneux S, Fenner L, Hsieh MH. 2017. Prevalence and clinical relevance of helminth co-infections among tuberculosis patients in urban Tanzania. PLoS Negl Trop Dis 11:e0005342.
197.
Sikalengo G, Hella J, Mhimbira F, Rutaihwa LK, Bani F, Ndege R, Sasamalo M, Kamwela L, Said K, Mhalu G, Mlacha Y, Hatz C, Knopp S, Gagneux S, Reither K, Utzinger J, Tanner M, Letang E, Weisser M, Fenner L. 2018. Distinct clinical characteristics and helminth co-infections in adult tuberculosis patients from urban compared to rural Tanzania. Infect Dis Poverty 7:24.
198.
Bettencourt PJG, Joosten SA, Lindestam Arlehamn CS, Behr MA, Locht C, Neyrolles O. 2021. 100 years of the Bacillus Calmette-Guérin vaccine. Vaccine 39:7221–7222.
199.
Elias D, Akuffo H, Thors C, Pawlowski A, Britton S. 2005. Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice. Clin Exp Immunol 139:398–404.
200.
Elias D, Akuffo H, Pawlowski A, Haile M, Schön T, Britton S. 2005. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine 23:1326–1334.
201.
Gopal R, Monin L, Torres D, Slight S, Mehra S, McKenna KC, Fallert Junecko BA, Reinhart TA, Kolls J, Báez-Saldaña R, et al. 2013. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am J Respir Crit Care Med 188:1137–1146.
202.
Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA, Mehra S, Selman M, Becerril-Villanueva E, Baquera-Heredia J, Pavon L, Kaushal D, Reinhart TA, Randall TD, Khader SA. 2013. CXCR5+ T helper cells mediate protective immunity against tuberculosis. J Clin Invest 123:712–726.
203.
Monin L, Griffiths KL, Lam WY, Gopal R, Kang DD, Ahmed M, Rajamanickam A, Cruz-Lagunas A, Zúñiga J, Babu S, Kolls JK, Mitreva M, Rosa BA, Ramos-Payan R, Morrison TE, Murray PJ, Rangel-Moreno J, Pearce EJ, Khader SA. 2015. Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. J Clin Invest 125:4699–4713.
204.
Munder M. 2009. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 158:638–651.
205.
El-Gayar S, Thüring-Nahler H, Pfeilschifter J, Röllinghoff M, Bogdan C. 2003. Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. J Immunol 171:4561–4568.
206.
Toulza F, Tsang L, Ottenhoff THM, Brown M, Dockrell HM. 2016. Mycobacterium tuberculosis-specific CD4+ T-cell response is increased, and treg cells decreased, in anthelmintic-treated patients with latent TB. Eur J Immunol 46:752–761.
207.
Sharma SK, Mohan A, Kadhiravan T. 2005. HIV-TB co-infection: epidemiology, diagnosis & management. Indian J Med Res 121:550–567.
208.
DiNardo AR, Mace EM, Lesteberg K, Cirillo JD, Mandalakas AM, Graviss EA, Orange JS, Makedonas G. 2016. Schistosome soluble egg antigen decreases Mycobacterium tuberculosis–specific CD4+ T-cell effector function with concomitant arrest of macrophage phago-lysosome maturation. J Infect Dis 214:479–488.
209.
DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A, Maphalala G, Secor WE, Mejia R, Orange JS, Coarfa C, Bhalla KN, Graviss EA, Mandalakas AM, Makedonas G. 2018. Schistosomiasis induces persistent DNA methylation and tuberculosis-specific immune changes. J Immunol 201:124–133.
210.
Harari A, Rozot V, Bellutti Enders F, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jaton K, Faouzi M, Day CL, Hanekom WA, Bart P-A, Pantaleo G. 2011. Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 17:372–376.
211.
Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, Salgame P. 2011. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J Exp Med 208:1863–1874.
212.
Schick J, Altunay M, Lacorcia M, Marschner N, Westermann S, Schluckebier J, Schubart C, Bodendorfer B, Christensen D, Alexander C, Wirtz S, Voehringer D, da Costa CP, Lang R. 2023. IL-4 and helminth infection downregulate MINCLE-dependent macrophage response to Mycobacteria and Th17 adjuvanticity. Elife 12:e72923.
213.
Togarsimalemath SK, Pushpamithran G, Schön T, Stendahl O, Blomgran R. 2021. Helminth antigen exposure enhances early immune control of Mycobacterium tuberculosis in monocytes and macrophages. J Innate Immun 13:148–163.
214.
Aira N, Andersson AM, Singh SK, McKay DM, Blomgran R. 2017. Species dependent impact of helminth-derived antigens on human macrophages infected with Mycobacterium tuberculosis: direct effect on the innate anti-mycobacterial response. PLoS Negl Trop Dis 11:e0005390.
215.
McLaughlin TA, Khayumbi J, Ongalo J, Tonui J, Campbell A, Allana S, Gurrion Ouma S, Odhiambo FH, Gandhi NR, Day CL. 2020. CD4 T cells in Mycobacterium tuberculosis and Schistosoma mansoni co-infected individuals maintain functional Th1 responses. Front Immunol 11:127.
216.
Bewket G, Kiflie A, Abate E, Stendahl O, Schön T, Blomgran R. 2021. Helminth species specific expansion and increased TNF-alpha production of non-classical monocytes during active tuberculosis. PLoS Negl Trop Dis 15:e0009194.
217.
Kiflie A, Bewket G, Abate E, Schön T, Blomgran R. 2021. Differential effects of asymptomatic Ascaris lumbricoides, Schistosoma mansoni or hook worm infection on the frequency and TGF-beta-producing capacity of regulatory T cells during active tuberculosis. Tuberculosis (Edinb) 131:102126.
218.
McLaughlin TA, Khayumbi J, Ongalo J, Matete D, Tonui J, Muchiri B, Sasser LE, Campbell A, Allana S, Ouma SG, Hayara FO, Gandhi NR, Day CL. 2020. Adults from Kisumu, Kenya have robust γδ T cell responses to Schistosoma mansoni, which are modulated by tuberculosis. PLoS Negl Trop Dis 14:e0008764.
219.
Dennison CL, de Oliveira LB, Fraga LA de O, E Lima RS, Ferreira JA, Clennon JA, de Mondesert L, Stephens J, Magueta EB, Castelo Branco A, Rezende M de C, Negrão-Corrêa D, de Faria Grossi MA, Fairley JK. 2021. Mycobacterium leprae-helminth co-infections and vitamin D deficiency as potential risk factors for leprosy: a case-control study in south-eastern Brazil. Int J Infect Dis 105:261–266.
220.
Phillips DA, Ferreira JA, Ansah D, Teixeira HS, Kitron U, Filippis T de, Alcântara M de, Fairley JK. 2017. A tale of two neglected tropical infections: using GIS to assess the spatial and temporal overlap of schistosomiasis and leprosy in a region of Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 112:275–280.
221.
Emerson LE, Anantharam P, Yehuala FM, Bilcha KD, Tesfaye AB, Fairley JK. 2020. Poor WASH (water, sanitation, and hygiene) conditions are associated with leprosy in North Gondar, Ethiopia. Int J Environ Res Public Health 17:1–10.
222.
2015. WHO Estimates of the Global Burden of Foodborne Diseases: Foodborne Disease Burden Epidemiology Reference Group 2007-2015. Available from: https://www.who.int/publications/i/item/9789241565165
223.
Salmonella Homepage | CDC. n.d. Available from: https://www.cdc.gov/salmonella/index.html
224.
Fierer J. 2022. Invasive non-typhoidal Salmonella (iNTS) infections. Clin Infect Dis 75:732–738.
225.
Dandekar T, Astrid F, Jasmin P, Hensel M. 2012. Salmonella enterica: a surprisingly well-adapted intracellular lifestyle. Front Microbiol 3:164.
226.
Eng S-K, Pusparajah P, Ab Mutalib N-S, Ser H-L, Chan K-G, Lee L-H. 2015. Salmonella: a review on pathogenesis, epidemiology and antibiotic resistance. Frontiers in Life Science 8:284–293.
227.
Darby J, Sheorey H. 2008. Searching for Salmonella. Aust Fam Physician 37:806–810.
228.
Trawinski H, Wendt S, Lippmann N, Heinitz S, von Braun A, Lübbert C. 2020. Typhoid and Paratyphoid fever. Z Gastroenterol 58:160–170.
229.
Information for Healthcare Professionals | Salmonella | CDC. https://www.cdc.gov/salmonella/general/technical.html.
230.
Mastroeni P, Rossi O. 2020. Antibodies and protection in systemic Salmonella infections: do we still have more questions than answers Infect Immun 88:e00219-20.
231.
Huang FC. 2021. The interleukins orchestrate mucosal immune responses to Salmonella infection in the intestine. Cells 10:3492.
232.
Ingram JP, Brodsky IE, Balachandran S. 2017. Interferon–γ in Salmonella pathogenesis: new tricks for an old dog. Cytokine 98:27–32.
233.
Rogers AWL, Tsolis RM, Bäumler AJ. 2020. Salmonella versus the microbiome. Microbiol Mol Biol Rev 85.
234.
Bajinka O, Qi M, Barrow A, Touray AO, Yang L, Tan Y. 2021. Pathogenicity of Salmonella during Schistosoma-Salmonella co-infections and the importance of the gut microbiota. Curr Microbiol 79:26.
235.
Muniz-Junqueira MI, Tosta CE, Prata A. 2009. Schistosoma-associated chronic septicemic salmonellosis: evolution of knowledge and immunopathogenic mechanisms. Rev Soc Bras Med Trop 42:436–445.
236.
Bourée P, Botterel F, Romand S. 2002. Delayed Salmonella bacteriuria in a patient infected with Schistosoma haematobium. J Egypt Soc Parasitol 32:355–360.
237.
Strausbaugh LJ, Farid Z, Higashi GI, Bassily S. 1978. Renal amyloidosis with nephrotic syndrome in two patients with Schistosomiasis mansoni and chronic salmonellosis. Am J Trop Med Hyg 27:919–923.
238.
Marege A, Seid M, Boke B, Thomas S, Arage M, Mouze N, Yohanes T, Woldemariam M, Manilal A. 2021. Prevalence of Schistosoma mansoni-Salmonella coinfection among patients in southern Ethiopia. New Microbes and New Infections 40:100842.
239.
Gendrel D, Kombila M, Beaudoin-Leblevec G, Richard-Lenoble D. 1994. Nontyphoidal salmonellal septicemia in gabonese children infected with Schistosoma intercalatum. Clin Infect Dis 18:103–105.
240.
Mbuyi-Kalonji L, Barbé B, Nkoji G, Madinga J, Roucher C, Linsuke S, Hermy M, Heroes A-S, Mattheus W, Polman K, Lutumba P, Phoba M-F, Lunguya O, Jacobs J. 2020. Non-typhoidal salmonella intestinal carriage in a Schistosoma mansoni endemic community in a rural area of the democratic republic of congo. PLoS Negl Trop Dis 14:e0007875.
241.
Chacha F, Mshana SE, Mirambo MM, Mushi MF, Kabymera R, Gerwing L, Schneiderhan W, Zimmermann O, Groß U. 2015. Salmonella Typhi meningitis in a 9-year old boy with urinary schistosomiasis: a case report. BMC Res Notes 8:64.
242.
Abdul-Fattah MM, Yossef SM, Ebraheem ME, Nasr ME, Hassan MA, Abdul Wahab SE. 1995. Schistosomal glomerulopathy: a putative role for commonly associated Salmonella infection. J Egypt Soc Parasitol 25:165–173.
243.
Martinelli R, Pereira LJ, Brito E, Rocha H. 1992. Renal involvement in prolonged Salmonella bacteremia: the role of schistosomal glomerulopathy. Rev Inst Med Trop Sao Paulo 34:193–198.
244.
Ashour DS, Othman AA. 2020. Parasite–bacteria interrelationship. Parasitol Res 119:3145–3164.
245.
Melhem RF, LoVerde PT. 1984. Mechanism of interaction of Salmonella and Schistosoma mansoni species. Infect Immun 44:274–281.
246.
Barnhill AE, Novozhilova E, Day TA, Carlson SA. 2011. Schistosoma mansoni-associated Salmonella resist antibiotics via specific fimbrial attachments to the flatworm. Parasit Vectors 4:123.
247.
Njunda AL, Oyerinde JP. 1996. Salmonella typhi infection in Schistosoma mansoni infected mice. West Afr J Med 15:24–30.
248.
Schramm G, Suwandi A, Galeev A, Sharma S, Braun J, Claes A-K, Braubach P, Grassl GA. 2018. Schistosome eggs impair protective Th1/Th17 immune responses against Salmonella infection. Front Immunol 9:2614.
249.
Lam HYP, Wu W-J, Liang T-R, Li H-C, Chang K-C, Peng S-Y. 2023. Salmonella typhimurium exacerbates injuries but resolves fibrosis in liver and spleen during Schistosoma mansoni infection. J Microbiol Immunol Infect 56:477–489.
250.
Muniz-Junqueira MI, Prata A, Tosta CE. 1992. Phagocytic and bactericidal function of mouse macrophages to Salmonella typhimurium in Schistosoma mansoni. Am J Trop Med Hyg 46:132–136.
251.
Muniz-Junqueira MI, Prata A, Tosta CE. 1997. Factors influencing phagocytosis of Salmonella typhimurium by macrophages in murine schistosomiasis. Rev Soc Bras Med Trop 30:101–106.
252.
Mikhail IA, Higashi GI, Mansour NS, Edman DC, Elwan SH. 1981. Salmonella paratyphi A in hamsters concurrently infected with Schistosoma mansoni. Am J Trop Med Hyg 30:385–393.
253.
Zhu X, Chen L, Wu J, Tang H, Wang Y. 2017. Salmonella typhimurium infection reduces Schistosoma japonicum worm burden in mice. Sci Rep 7:1349.
254.
Foxman B. 2002. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113 Suppl 1A:5S–13S.
255.
Harrington RD, Hooton TM. 2000. Urinary tract infection risk factors and gender. J Gend Specif Med 3:27–34.
256.
Doherty JF, Grant AD, Bryceson AD. 1995. Fever as the presenting complaint of travellers returning from the tropics. QJM 88:277–281.
257.
Nji CP, Assob JCN, Akoachere J-F, Yokota S. 2020. Predictors of urinary tract infections in children and antibiotic susceptibility pattern in the Buea health district. Biomed Res Int 2020:2176569.
258.
Eyong ME, Ikepeme EE, Ekanem EE. 2008. Relationship between Schistosoma haematobium infection and urinary tract infection among children in South Eastern, Nigeria. Niger Postgrad Med J 15:89–93.
259.
Adeyeba O, Ojeaga S. 2010. Urinary schistosomiasis and concomitant urinary tract pathogens among school children in metropoitan Ibadan, Nigeria. Afr J Biomed Res 5:103–107.
260.
Chai Z-W, Xu Q-C, Xu C-M. 2014. Schistosomiasis haematobia misdiagnosed as urinary trace infection: one case report. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 26:I.
261.
Jones J. 1977. Schistosomiasis haematobium. JAMA 238:1275–1276.
262.
Seynabou L, Awa BD, Oumarou FD, Moustapha M, Makhtar C, Mamadou D, Rokhaya D, Mamadou LD, G eacute rard CD, Roughyatou K, Th eacute r egrave se D, Babacar F, Ahmad IS. 2016. Profile of bacterial and parasitic urinary infections in Saint Louis Senegal between 2000 and 2010. Afr J Microbiol Res 10:1061–1065.
263.
Gomes CM, Hisano M, Machado LR, Figueiredo JA, Lucon AM, Trigo-Rocha FE. 2005. Urological manifestations of chronic schistosomal myeloradiculopathy. BJU Int 96:853–856.
264.
el Hawey A, Massoud A, Badr el Din N, Waheeb A, Abd-el Hamid S. 1989. Bacterial flora in hepatic encephalopathy in bilharzial and non-bilharzial patients. J Egypt Soc Parasitol 19:797–804.
265.
Sobh MA, el-Agroudy AE, Moustafa FE, Shokeir AA, el-Shazly A, Ghoneim MA. 1992. Impact of schistosomiasis on patient and graft outcome after kidney transplantation. Nephrol Dial Transplant 7:858–864.
266.
Gomes CM, Trigo-Rocha F, Arap MA, Gabriel AJ, Alaor de Figueiredo J, Arap S. 2002. Schistosomal myelopathy: urologic manifestations and urodynamic findings. Urology 59:195–200.
267.
Nmorsi OPG, Kwandu UNCD, Ebiaguanye LM. 2007. Schistosoma haematobium and urinary tract pathogens co-infections in a rural community of Edo State, Nigeria. J Commun Dis 39:85–90.
268.
J.Amoo K, Amoo O, Oke A, Adegboyega T. 2017. Prevalence of urinary tract infection (UTI) and concomitant urinary schistosomiasis among primary school children in Remo North local government, Ogun state, Nigeria. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) 16:68–73.
269.
Ayoade F, Moro DD, Ebene OL. 2013. Prevalence and antimicrobial susceptibility pattern of asymptomatic urinary tract infections of bacterial and parasitic origins among university students in redemption camp, Ogun state, Nigeria. OJMM 03:219–226.
270.
Kone KJ, Onifade AK, Dada EO. 2023. Risk factors affecting the occurrence of urinary schistosomiasis and urinary tract infections in some communities of Ondo State, Nigeria. J Water Health 21:27–34.
271.
Soyannwo MA, Ogbechi ME, Adeyeni GA, Soyeni AI, Lipede MR, Lucas AO. 1978. Studies on the prevalence of renal disease and hypertension in relation to schistosomiasis. III. Proteinuria, haematuria, pyuria and bacteriuria in the rural community of Nigeria. Niger Med J 8:451–464.
272.
Ossai OP, Dankoli R, Nwodo C, Tukur D, Nsubuga P, Ogbuabor D, Ekwueme O, Abonyi G, Ezeanolue E, Nguku P, Nwagbo D, Idris S, Eze G. 2014. Bacteriuria and urinary schistosomiasis in primary school children in rural communities in Enugu State, Nigeria, 2012. Pan Afr Med J 18:15.
273.
Chidinma Ursula Uwandu, Joy Nkeiruka Dike-Ndudim, Chizaram Winners Ndubueze2022. Epidemiological studies on urinary schistosomiasis and bacterial co-infection in some rural communities of Abia State. World J Bio Pharm Health Sci 10:065–072.
274.
Anosike JC et al. 2001. Endemicity of urinary schistosomiasis in north central zone of Abia state, Nigeria. Int J Environ Hlth Human Develop 1:6–15.
275.
Nwachukwu IO et al. 2018. Urinary schistosomiasis and concomitant bacteriuria among school age children in some parts of Owerri, IMO state. INTERNATIONAL JOURNAL OF RESEARCH IN ADVANCE ENGINEERING 3:107–115.
276.
Mahmoud KM, Sobh MA, El-Agroudy AE, Mostafa FE, Baz ME, Shokeir AA, Ghoneim MA. 2001. Impact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years’ follow-up. Nephrol Dial Transplant 16:2214–2221.
277.
Wishahi MM, el-Sherbeni E, el-Baz H. 1984. Granulomatous cystitis: a reversible lesion in children. Eur Urol 10:368–369.
278.
Usaini B, Taura D, Koki Y, et al. 2006. Studies on seasonal variation in the occurrences of Schistosoma haematobium and bacterial urinary infections among school age children in Kano. IOSR J Pharm Biol Sci 10:27–33.
279.
Alagha B, Dada EO. 2021. Urinary schistosomiasis and asymptomatic bacteriuria among individuals of Ipogun, Nigeria: detection of predominant microorganisms and antibiotic susceptibility profile. jmhs 2:70–80.
280.
Nimorsi OP, Egwunyenga AO, Bajomo DO. 2001. Survey of urinary schistosomiasis and trichomoniasis in a rural community in Edo State, Nigeria. J Commun Dis 33:96–101.
281.
Gadoth A, Mvumbi G, Hoff NA, Musene K, Mukadi P, Ashbaugh HR, Doshi RH, Javanbakht M, Gorbach P, Okitolonda-Wemakoy E, Klausner JD, Rimoin AW. 2019. Urogenital schistosomiasis and sexually transmitted coinfections among pregnant women in a schistosome-endemic region of the democratic republic of Congo. Am J Trop Med Hyg 101:828–836.
282.
Hennequin C, Bourée P, Halfon P. 1991. Salmonella paratyphi A urinary infection in Schistosoma mansoni bilharziasis. Rev Med Interne 12:141–142.
283.
Uwaezuoke J, Anosike J, Udujih O, Onyeka P. 2010. Epidemiological and bacteriological studies on vesical schistosomiasis in Ikwo area, Ebonyi state, Nigeria. JASEM 12:75–80.
284.
Uneke CJ, Ugwuoke-Adibuah S, Nwakpu KO, Ngwu BA. 2009. An assessment of Schistosoma haematobium infection and urinary tract bacterial infection amongst school children in rural eastern Nigeria. IJLM 4.
285.
Hsieh YJ, Fu CL, Hsieh M. 2013. Interleukin-4 signaling promotes bacteriuria during urinary tract co-infection. J Urol 189:e470.
286.
Hsieh Y-J, Fu C-L, Hsieh MH, Appleton JA. 2014. Helminth-induced interleukin-4 Abrogates invariant natural killer T cell activation-associated clearance of bacterial infection. Infect Immun 82:2087–2097.
287.
Mbanefo EC, Le L, Pennington LF, Hsieh Y-J, Odegaard JI, Lapira K, Jardetzky TS, Falcone FH, Hsieh MH. 2020. IPSE, a urogenital parasite-derived immunomodulatory molecule, suppresses bladder pathogenesis and anti-microbial peptide gene expression in bacterial urinary tract infection. Parasit Vectors 13:615.
288.
Burrell CJ, Howard CR, Murphy FA. 2017. Epidemiology of viral infections. Fenner and White’s Medical Virology 185.
289.
WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Available from: https://covid19.who.int
290.
Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, Takahashi S, Tatem AJ, Wagner CE, Wang L-F, Wesolowski A, Metcalf CJE. 2022. Infectious disease in an era of global change. Nat Rev Microbiol 20:193–205.
292.
Feehan J, Apostolopoulos V. 2021. Is COVID-19 the worst pandemic Maturitas 149:56–58.
293.
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ, Robertson DL, COVID-19 Genomics UK (COG-UK) Consortium. 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409–424.
294.
He X, Hong W, Pan X, Lu G, Wei X. 2021. SARS‐CoV‐2 omicron variant: characteristics and prevention. MedComm (2020) 2:838–845.
295.
Chang T, Jung BK, Chai JY, Cho Si. 2022. The notable global heterogeneity in the distribution of COVID-19 cases and the association with pre-existing parasitic diseases. PLoS Negl Trop Dis 16:e0010826.
296.
Nguimkeu P, Tadadjeu S. 2021. Why is the number of COVID-19 cases lower than expected in Sub-Saharan Africa? A cross-sectional analysis of the role of demographic and geographic factors. World Dev 138:105251.
297.
Favas C, Jarrett P, Ratnayake R, Watson OJ, Checchi F. 2022. Country differences in transmissibility, age distribution and case-fatality of SARS-CoV-2: a global ecological analysis. Int J Infect Dis 114:210–218.
298.
Veldhoen M, Bertoletti A. 2023. SARS-CoV-2 clearance after breakthrough infection correlates with fit and happy T cells. Immunol Cell Biol 101:587–589.
299.
Koutsakos M, Reynaldi A, Lee WS, Nguyen J, Amarasena T, Taiaroa G, Kinsella P, Liew KC, Tran T, Kent HE, Tan H-X, Rowntree LC, Nguyen THO, Thomas PG, Kedzierska K, Petersen J, Rossjohn J, Williamson DA, Khoury D, Davenport MP, Kent SJ, Wheatley AK, Juno JA. 2023. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity 56:879–892.
300.
Bernal E, García-Villalba E, Pons E, Vicente MR, Tomás C, Minguela A, Hernández MD, Puche G, Carter P, Martinez M, Alcaraz A, Nuñez ML, Sancho N, Villalba MC, Cano A, Muñoz A, Báguena C. 2023. Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients. Med Clin (Barc) 160:476–483.
301.
Bradbury RS, Piedrafita D, Greenhill A, Mahanty S. 2020. Will helminth co-infection modulate COVID-19 severity in endemic regions?. Nat Rev Immunol 20:342–342.
302.
Sánchez-Marqués R, Mas-Coma S, Salas-Coronas J, Boissier J, Bargues MD. 2022. Research on schistosomiasis in the era of the COVID-19 pandemic: a bibliometric analysis. Int J Environ Res Public Health 19:8051.
303.
Wolday D, Gebrecherkos T, Arefaine ZG, Kiros YK, Gebreegzabher A, Tasew G, Abdulkader M, Abraha HE, Desta AA, Hailu A, Tollera G, Abdella S, Tesema M, Abate E, Endarge KL, Hundie TG, Miteku FK, Urban BC, Schallig H, Harris VC, de Wit TFR. 2021. Effect of co-infection with intestinal parasites on COVID-19 severity: a prospective observational cohort study. EClinicalMedicine 39:101054.
304.
Sinha P, Matthay MA, Calfee CS. 2020. Is a ‘cytokine storm’ relevant to COVID-19. JAMA Intern Med 180:1152–1154.
305.
Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Elhadad H, Alexiou A, Papadakis M, Ogaly HA, Elgazzar AM, Batiha G-S. 2023. Immunological interactions in helminths-SARS CoV-2 coinfection: could old enemy be a friend today?. Parasite Immunol 45:e12982.
306.
Dantas NM, Andrade LA, Paz W da, Borges WN, Barbosa VGB, Hora D da, Silva C da, do Carmo RF, Souza C de, Santos ADD, Wanderley FS, Negrão-Corrêa DA, Fujiwara RT, Bezerra-Santos M, Porto WJN. 2023. Impact of the COVID-19 pandemic on the actions of the Schistosomiasis Control Program in an endemic area in Northeastern Brazil. Acta Trop 240:106859.
307.
Li G, Xu D, Hu Y, Xu M, Zhang L, Du X, Zhang L, Sun C, Xie Y, Tan X. 2022. Impact of the coronavirus disease 2019 lockdown on Schistosoma host Oncomelania hupensis density in Wuhan. Acta Trop 226:106224.
308.
Kura K, Ayabina D, Toor J, Hollingsworth TD, Anderson RM. 2021. Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies. Trans R Soc Trop Med Hyg 115:236–244.
309.
About HIV/AIDS | HIV Basics | HIV/AIDS | CDC. https://www.cdc.gov/hiv/basics/whatishiv.html.
310.
HIV and AIDS Epidemic Global Statistics | HIV.Gov. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics/
312.
Gubser C, Pitman MC, Lewin SR. 2019. CD4+ T cell signatures in HIV infection. Nat. Immunol 20:948–950.
313.
Bhattacharyya, S., Crain, C. R., Goldberg, B. & Gaiha, G. D. Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development. Curr Opin HIV AIDS 18, 257–263 (2023).
314.
Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M, Koup RA. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95–98.
315.
Furch BD, Koethe JR, Kayamba V, Heimburger DC, Kelly P. 2020. Interactions of Schistosoma mansoni and HIV in sub-Saharan Africa: a systematic review. Am J Trop Med Hyg 102:711–718.
316.
Secor WE. 2012. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. Curr Opin HIV AIDS 7:254–259.
317.
Downs JA, Dupnik KM, van Dam GJ, Urassa M, Lutonja P, Kornelis D, de Dood CJ, Hoekstra P, Kanjala C, Isingo R, Peck RN, Lee MH, Corstjens P, Todd J, Changalucha JM, Johnson WD, Fitzgerald DW. 2017. Schistosoma mansoni and HIV infection in a Ugandan population with high HIV and helminth prevalence. PLoS Negl Trop Dis 11:e0005968.
318.
Ciccone EJ, Greenwald JH, Lee PI, Biancotto A, Read SW, Yao MA, Hodge JN, Thompson WL, Kovacs SB, Chairez CL, Migueles SA, Kovacs JA, Margolis LB, Sereti I. 2011. CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. J Virol 85:5880–5888.
319.
Midzi N, Mduluza T, Mudenge B, Foldager L, Leutscher PDC. 2017. Decrease in seminal HIV-1 RNA load after praziquantel treatment of urogenital cchistosomiasis coinfection in HIV-positive men—an observational study. Open Forum Infect Dis 4:ofx199.
320.
Yegorov S, Joag V, Galiwango RM, Good SV, Mpendo J, Tannich E, Boggild AK, Kiwanuka N, Bagaya BS, Kaul R. 2019. Schistosoma mansoni treatment reduces HIV entry into cervical CD4+ T cells and induces IFN-I pathways. Nat Commun 10:2296.
321.
Chen Y, Lin H, Cole M, Morris A, Martinson J, Mckay H, Mimiaga M, Margolick J, Fitch A, Methe B, Srinivas VR, Peddada S, Rinaldo CR. 2021. Signature changes in gut microbiome are associated with increased susceptibility to HIV-1 infection in MSM. Microbiome 9:237.
322.
Woodall PA, Kramer MR. 2018. Schistosomiasis and Infertility in East Africa. Am J Trop Med Hyg 98:1137–1144.
323.
Plesniarski A, Siddik AB, Su RC. 2021. The microbiome as a key regulator of female genital tract barrier function. Front Cell Infect Microbiol 11:790627.
324.
Brenchley JM, Douek DC. 2008. HIV infection and the gastrointestinal immune system. Mucosal Immunol 1:23–30.
325.
Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson A-L, Chege GK, Silvestri G. 2018. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. PLoS Pathog 14:e1007182.
326.
Mouser EEIM, Pollakis G, Paxton WA. 2012. Effects of helminths and Mycobacterium tuberculosis infection on HIV-1: a cellular immunological perspective. Curr Opin HIV AIDS 7:260–267.
327.
Gazzinelli-Guimaraes PH, Nutman TB. 2018. Helminth parasites and immune regulation. F1000Res 7:1685.
328.
Kallestrup P, Zinyama R, Gomo E, Butterworth AE, van Dam GJ, Erikstrup C, Ullum H. 2005. Schistosomiasis and HIV-1 infection in rural Zimbabwe: implications of coinfection for excretion of eggs. J INFECT DIS 191:1311–1320.
329.
Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, Downs JA, Carvalho EM. 2011. Examining the relationship between urogenital schistosomiasis and HIV infection. PLoS Negl Trop Dis 5:e1396.
330.
Colombe S, Corstjens P, de Dood CJ, Miyaye D, Magawa RG, Mngara J, Kalluvya SE, van Lieshout L, van Dam GJ, Downs JA. 2018. HIV-1 viral loads are not elevated in individuals co-infected with Schistosoma mansoni spp. After adjustment for duration of HIV-1 infection. Front Immunol 9:2005.
331.
Colombe S, Machemba R, Mtenga B, Lutonja P, Kalluvya SE, de Dood CJ, Hoekstra PT, van Dam GJ, Corstjens P, Urassa M, Changalucha JM, Todd J, Downs JA. 2018. Impact of schistosome infection on long-term HIV/AIDS outcomes. PLoS Negl Trop Dis 12:e0006613.
332.
Yang Y, Xiao P-L, Yang Y, Gao J-C, Shi Y, Cheng W-T, Chen Y, Song X-X, Jiang Q-W, Zhou Y-B. 2018. Immune dysfunction and coinfection with human immunodeficiency virus and Schistosoma japonicum in Yi people. J Immunol Res 2018:6989717.
333.
Mazigo HD, Dunne DW, Morona D, Lutufyo TE, Kinung’hi SM, Kaatano G, Nuwaha F. 2015. Periportal fibrosis, liver and spleen sizes among S. mansoni mono or co-infected individuals with human immunodeficiency virus-1 in fishing villages along Lake Victoria shores, North-Western, Tanzania. Parasit Vectors 8:260.
334.
Ocama P, Opio KC, Seremba E, Ajal P, Apica BS, Aginya EO. 2017. The burden, pattern and factors that contribute to periportal fibrosis in HIV-infected patients in an S. mansoni endemic rural Uganda. Afr Health Sci 17:301–307.
335.
Marti AI, Colombe S, Masikini PJ, Kalluvya SE, Smart LR, Wajanga BM, Jaka H, Peck RN, Downs JA, Friedman JF. 2017. Increased hepatotoxicity among HIV-infected adults co-infected with Schistosoma mansoni in Tanzania: a cross-sectional study. PLoS Negl Trop Dis 11:e0005867.
336.
Colombe S, Lee MH, Masikini PJ, van Lieshout L, de Dood CJ, Hoekstra PT, Corstjens PLAM, Mngara J, van Dam GJ, Downs JA. 2018. Decreased sensitivity of Schistosoma mansoni sp. egg microscopy in women and HIV-infected individuals. Am J Trop Med Hyg 98:1159–1164.
337.
Sanya RE, Muhangi L, Nampijja M, Nannozi V, Nakawungu PK, Abayo E, Webb EL, Elliott AM, LaVIISWA study team. 2015. Schistosoma mansoni and HIV infection in a Ugandan population with high HIV and helminth prevalence. Trop Med Int Health 20:1201–1208.
338.
UNAIDS. 2020. Update: 90–90–90: Good Progress, but the World Is off-Track for Hitting the 2020 Targets. Available from: https://www.unaids.org/en/resources/presscentre/featurestories/2020/september/20200921_90-90-90
340.
Jacobsen KH. 2018. Globalization and the changing epidemiology of hepatitis A virus. Cold Spring Harb Perspect Med 8:a031716.
341.
Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. 2012. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 55:988–997.
342.
MacLachlan JH, Cowie BC. 2015. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med 5:a021410.
343.
Spearman CW, Dusheiko GM, Hellard M, Sonderup M. 2019. Hepatitis C. The Lancet 394:1451–1466.
344.
Sagnelli C, Sagnelli E, Russo A, Pisaturo M, Occhiello L, Coppola N. 2021. HBV/HDV co-infection: epidemiological and clinical changes, recent knowledge and future challenges. Life (Basel) 11:1–17.
345.
Nucleoside Analogues. 2012. In Livertox: Clinical and research information on drug-induced liver injury. In National Institute of diabetes and digestive and kidney diseases
346.
Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. 2021. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B. Drug Saf 44:133–165.
347.
Baumert TF, Berg T, Lim JK, Nelson DR. 2019. Status of direct-acting antiviral therapy for HCV infection and remaining challenges. Gastroenterology 156:431–445.
348.
Stapleton JT. 1995. Host immune response to hepatitis A virus. J Infect Dis 171 Suppl 1:S9–14.
349.
Shin EC, Sung PS, Park SH. 2016. Immune responses and Immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 16:509–523.
350.
Chatzileontiadou DSM, Sloane H, Nguyen AT, Gras S, Grant EJ. 2020. The many faces of CD4+ T cells: immunological and structural characteristics. Int J Mol Sci 22:1–27.
351.
Reina-Campos M, Scharping NE, Goldrath AW. 2021. CD8+ T cell metabolism in infection and cancer. Nat Rev Immunol 21:718–738.
352.
Lam JH, Smith FL, Baumgarth N. 2020. B cell activation and response regulation during viral infections. Viral Immunol 33:294–306.
353.
Xu C, Chen J, Chen X. 2021. Host innate immunity against hepatitis viruses and viral immune evasion. Front Microbiol 12:740464.
354.
Omar HH. 2019. Impact of chronic schistosomiasis and HBV/HCV co-infection on the liver: current perspectives. Hepat Med 11:131–136.
355.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342.
356.
Omar HH, Taha SA, Hassan WH, Omar HH. 2017. Impact of schistosomiasis on increase incidence of occult hepatitis B in chronic hepatitis C patients in Egypt. J Infect Public Health 10:761–765.
357.
Khatami A, Bahadory S, Ghorbani S, Saadati H, Zarei M, Soleimani A, Zibaei M. 2021. Two rivals or colleagues in the liver? Hepatit B virus and Schistosoma mansoni co-infections: a systematic review and meta-analysis. Microb Pathog 154:104828.
358.
Zhang Y, Xie Y, Chen Q, Chen X, Dong Z, Tan X. 2020. Prevalence and co-infection of schistosomiasis/hepatitis B among rural populations in endemic areas in Hubei, China. Trans R Soc Trop Med Hyg 114:155–161.
359.
Mavilia MG, Wu GY. 2018. HBV-HCV coinfection: viral interactions, management, and viral reactivation. J Clin Transl Hepatol 6:296–305.
360.
El-Shabrawi MH, Kamal NM. 2013. Burden of pediatric hepatitis C. World J Gastroenterol 19:7880–7888.
361.
Abruzzi A, Fried B, Alikhan SB. 2016. Coinfection of Schistosoma mansoni species with hepatitis B or hepatitis C viruses. Adv Parasitol 91:111–231.
362.
Abdel-Rahman M, El-Sayed M, El Raziky M, Elsharkawy A, El-Akel W, Ghoneim H, Khattab H, Esmat G. 2013. Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response. World J Gastroenterol 19:2691–2696.
363.
Van-Lume DS de M, Albuquerque M de FPM de, Souza AI de, Domingues ALC, Lopes EP de A, Morais CNL de, Montenegro SML. 2013. Association between Schistosomiasis mansoni and hepatitis C: systematic review. Rev Saude Publica 47:414–424.
364.
Gasim GI, Bella A, Adam I. 2015. Schistosomiasis, hepatitis B and hepatitis C co-infection. Virol J 12:19.
365.
Muir R, Metcalf T, Fourati S, Bartsch Y, Kyosiimire-Lugemwa J, Canderan G, Alter G, Muyanja E, Okech B, Namatovu T, et al. 2023. Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted hepatitis B vaccination immune responses. PLoS Negl Trop Dis 17:e0011089.
366.
Bullington BW, Klemperer K, Mages K, Chalem A, Mazigo HD, Changalucha J, Kapiga S, Wright PF, Yazdanbakhsh MM, Downs JA. 2021. Effects of schistosomes on host anti-viral immune response and the acquisition, virulence, and prevention of viral infections: a systematic review. PLoS Pathog 17:e1009555.
367.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. 2021. Hepatocellular carcinoma. Nat Rev Dis Primers 7:1–28.
368.
Gohary AA, Elyamany A, Abdalla D, Abolfadl A. 2020. Comparison of hepatic and splenic stiffness in chronic hepatitis C infection with and without schistosomal infection; correlation with hepatic histopathological changes. Clin Exp Hepatol 6:275–281.
369.
Loffredo-Verde E, Bhattacharjee S, Malo A, Festag J, Kosinska AD, Ringelhan M, Rim Sarkar S, Steiger K, Heikenwaelder M, Protzer U, Prazeres da Costa CU. 2020. Dynamic, helminth-induced immune modulation influences the outcome of acute and chronic hepatitis B virus infection. J Infect Dis 221:1448–1461.
370.
Marchese V, Beltrame A, Angheben A, Marocco S, Gaeta GB, Bisoffi Z. 2020. The impact of schistosomiasis co-infection in the presentation of viral hepatitis B in migrants: an observational study in non-endemic area. Travel Med Infect Dis 35:101467.
371.
Rizzo GEM, Cabibbo G, Craxì A. 2022. Hepatitis B virus-associated hepatocellular carcinoma. Viruses 14:986.
372.
Andrade JR, Silva LD, Guimaraes CM, Bassetti-Soares E, Cambraia RD, Couto OFM, Teixeira R. 2014. Chronic hepatitis B and liver Schistosomiasis: A deleterious Association. Transactions of the Royal Society of Tropical Medicine and Hygiene 108:159–164.
373.
Badr RM, Mahomed FF, Fattah SA, Strickland GT, Kamel M, Ghaffar YA. 1991. The impact of endemic schistosomiasis on acute viral hepatitis. Am J Trop Med Hyg 45:743–750.
374.
Azer SA, Limaiem F. 2023. Cytomegalovirus colitis
375.
Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. 2019. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol 29:e2034.
376.
Cannon MJ, Schmid DS, Hyde TB. 2010. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20:202–213.
377.
About Cytomegalovirus and Congenital CMV Infection | CDC. https://www.cdc.gov/cmv/overview.html.
378.
van Zuylen WJ, Hamilton ST, Naing Z, Hall B, Shand A, Rawlinson WD. 2014. Congenital cytomegalovirus infection: clinical presentation, epidemiology, diagnosis and prevention. Obstet Med 7:140–146.
379.
Congenital CMV and Hearing Loss | CDC. https://www.cdc.gov/cmv/hearing-loss.html.
380.
Lérias JR, Paraschoudi G, Silva I, Martins J, de Sousa E, Condeço C, Figueiredo N, Carvalho C, Dodoo E, Jäger E, Rao M, Maeurer M. 2019. Clinically relevant immune responses against cytomegalovirus: implications for precision medicine. IJMS 20:1986.
381.
Cicin-Sain L. 2019. Cytomegalovirus memory inflation and immune protection. Med Microbiol Immunol 208:339–347.
382.
Forte E, Zhang Z, Thorp EB, Hummel M. 2020. Cytomegalovirus latency and reactivation: an intricate interplay with the host immune response. Front Cell Infect Microbiol 10:130.
383.
Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296:1323–1326.
384.
Gao Y, Zhang X, Jiang T, Zhou H, Liu H, Hu Y, Cao J, Hsieh MH. 2023. Inhibition of hepatic natural killer cell function via the TIGIT receptor in schistosomiasis-induced liver fibrosis. PLoS Pathog 19:e1011242.
385.
Hou X, Yu F, Man S, Huang D, Zhang Y, Liu M, Ren C, Shen J. 2012. Negative regulation of Schistosoma japonicum egg-induced liver fibrosis by natural killer cells. PLoS Negl Trop Dis 6:e1456.
387.
Madewell ZJ. 2020. Arboviruses and their vectors. South Med J 113:520–523.
388.
Viglietta M, Bellone R, Blisnick AA, Failloux AB. 2021. Vector specificity of arbovirus transmission. Front Microbiol 12:773211.
389.
Rodhain F. 1998. The idea of natural reservoir in arbovirology. Bull Soc Pathol Exot 91:279–282.
390.
Atkinson B, Hewson R. 2018. Emerging arboviruses of clinical importance in Central Asia. J Gen Virol 99:1172–1184.
391.
Rocklöv J, Dubrow R. 2020. Author correction: climate change: an enduring challenge for vector-borne disease prevention and control control (Nature Immunology, (2020), 21, 5, (479-483), 10.1038/s41590-020-0648-y). Nat Immunol 21:479–483. https://doi.org/10.1038/s41590-020-0692-7
392.
Campbell-Lendrum D, Manga L, Bagayoko M, Sommerfeld J. 2015. Climate change and vector-borne diseases: what are the implications for public health research and policy?. Philos Trans R Soc Lond B Biol Sci 370:20130552.
393.
Higuera A, Ramírez JD. 2019. Molecular epidemiology of dengue, yellow fever, Zika and Chikungunya arboviruses: an update. Acta Trop 190:99–111.
395.
Ogunlade ST, Meehan MT, Adekunle AI, Rojas DP, Adegboye OA, McBryde ES. 2021. A review: Aedes-borne arboviral infections, controls and Wolbachia-based strategies. Vaccines 9:32.
396.
Overgaard HJ, Dada N, Lenhart A, Stenström TAB, Alexander N. 2021. Integrated disease management: arboviral infections and Waterborne diarrhoea. Bull World Health Organ 99:583–592.
397.
Deol AK, Fleming FM, Calvo-Urbano B, Walker M, Bucumi V, Gnandou I, Tukahebwa EM, Jemu S, Mwingira UJ, Alkohlani A, Traoré M, Ruberanziza E, Touré S, Basáñez M-G, French MD, Webster JP. 2019. Schistosomiasis — assessing progress toward the 2020 and 2025 global goals. N Engl J Med 381:2519–2528.
398.
Alves LS, Estanislau C, Barreto L, Batista F, Toppa N. 2017. Concomitant testicular infection by Zika virus and Schistosoma mansoni in a Brazilian young boy. Rev Assoc Med Bras 63:500–503.
399.
Ahmed AFM, El-Sayad MH, Ali HS, El-Taweel HA. 2021. Impact of coinfection with Schistosoma mansoni on the antibody response to Helicobacter pylori. Acta Parasit 66:857–862.
400.
Rosadas C, Taylor GP. 2022. HTLV-1 and Co-infections. Front. Med 9.
401.
Pielok Ł, Frąckowiak K, Kłudkowska M. 2019. Disseminated skin rash and blood eosinophilia in a Polish traveler diagnosed Strongyloides stercoralis, Trichuris trichiura, Schistosoma mansoni sp. and Blastocystis sp. coinfection. Ann Parasitol 65:99–102.
402.
Fiamma M, Longoni SS, Siddig EE, Attene S, Astone V, Nicoletti A, Paglietti B, Santona A, Fele A, Ivaldi R, Logias F. 2020. Multi-parasite infection in an immigrant from Ghana: potential for new epidemic foci. J Infect Dev Ctries 14:1344–1348.
403.
McLaughlin TA, Nizam A, Hayara FO, Ouma GS, Campbell A, Khayumbi J, Ongalo J, Ouma SG, Shah NS, Altman JD, Kaushal D, Rengarajan J, Ernst JD, Blumberg HM, Waller LA, Gandhi NR, Day CL, Benkeser D. 2021. Schistosoma mansoni infection is associated with a higher probability of tuberculosis disease in HIV-infected adults in Kenya. J Acquir Immune Defic Syndr 86:157–163.
404.
Gordon MA, Zijlstra EE, Naus CWA, Visser LG, Molyneux ME, van Lieshout L. 2003. Schistosomiasis does not contribute to death or recurrence of nontyphoid Salmonella bacteremia in human immunodeficiency virus-infected Malawian adults. Clin Infect Dis 37:e177–e179.
405.
Dunne DW, Cooke A. 2005. A worm’s eye view of the immune system: consequences for evolution of human autoimmune disease. Nat Rev Immunol 5:420–426.
406.
Osakunor DNM, Ishida K, Lamanna OK, Rossi M, Dwomoh L, Hsieh MH, Cwiklinski K. 2022. Host tissue proteomics reveal insights into the molecular basis of Schistosoma haematobium-induced bladder pathology. PLoS Negl Trop Dis 16:e0010176.
407.
Buck JC, De Leo GA, Sokolow SH. 2020. Concomitant immunity and worm senescence may drive schistosomiasis epidemiological patterns: an ECO-evolutionary perspective. Immunol 11:490788.

Author Bios

Division of Experimental Medicine, McGill University, Montreal, Canada
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Canada
Dilhan Perera is completing his PhD in the division of Experimental Medicine, McGill University (Montreal, QC, Canada). Under the supervision of Dr. Momar Ndao, Dilhan’s current research focus is vaccine development and immunology for schistosomiasis and COVID-19. Dilhan earned his undergraduate degree in Microbiology and Immunology at McGill, and has spent time as a research assistant at the Mayo Clinic (Rochester, MN, USA) and KGK Science (London, ON, Canada) conducting in silico analyses of aneurysms and assisting with nutraceutical clinical trials, respectively. Since 2017, he has published eleven peer-reviewed manuscripts, both reviews and primary research, and serves as the secretary for the Food and Environmental Parasitology Network (Health Canada). Dilhan currently holds a Canadian Institutes of Health Research Doctoral Award, and has been awarded with several institutional presentation awards and awards dedicated to teaching, mentorship, and enhancing student learning.
Division of Experimental Medicine, McGill University, Montreal, Canada
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Canada
Cal Koger-Pease is completing their PhD in the division of Experimental Medicine, McGill University (Montreal, QC, Canada). Under the supervision of Dr. Momar Ndao, Cal’s current research focus is developing viral vectored vaccines and elucidating correlates of protection for schistosomiasis. Cal earned their undergraduate degree in Microbiology and Immunology at McGill, where they completed an undergraduate honours thesis focusing on short interfering RNA treatments for COVID-19. Since 2023, they have published two peer-reviewed manuscripts.
Department of Microbiology and Immunology, McGill University, Montreal, Canada
Kayla Paulini is completing her PhD in the department of Microbiology and Immunology at McGill University (Montreal, QC, Canada). Under the supervision of Dr. Greg Matlashewski, Kayla studies various phosphatases in Leishmania and how they pertain to infection. She earned her bachelor’s degree in Microbiology and Immunology at McGill University in 2017 after gaining research experience in three different labs working with Caulobacter crescentus, Pseudomonas aeruginosa, and Heligmosomoides bakeri. After her bachelor’s degree, Kayla worked as a lab technician in the food microbiology industry before returning to graduate school. Currently, Kayla holds a Fond de Recherche du Québec en Santé doctoral award.
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Canada
Department of Microbiology and Immunology, McGill University, Montreal, Canada
Mohamed Daoudi is a post-doctoral fellow in the Ndao lab in the department of Microbiology and Immunology at McGill University (Montreal, QC, Canada). He holds a PhD in Microbiology and Medical Entomology focusing on investigating geographical distribution and vectorial capacity of the Moroccan population of sand flies. His current research project focuses on the utilisation of extracellular vesicles to develop advanced methods for the early detection of infections, the creation of precise diagnostic tools, and the preventive measures against Tick-borne diseases and schistosomiasis. Mohamed has published nine peer-reviewed manuscripts since 2019, received the Federation of African Immunological Societies Award in 2019, and received a grant from the Italian Ministry of Foreign Affairs and International Cooperation in 2020.
Division of Experimental Medicine, McGill University, Montreal, Canada
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Canada
Department of Microbiology and Immunology, McGill University, Montreal, Canada
National Reference Centre for Parasitology, Research Institute of the McGill University Health Centre, Montreal, Canada
Momar Ndao is a Doctor of Veterinary Medicine, and earned his MSc and PhD in Tropical Medicine in International Health and Tropical Diseases at the Institute of Tropical Medicine (Antwerp, Belgium). He is currently an Associate Professor at McGill University in the Faculty of Medicine (Montreal, QC, Canada) and his research focuses on parasite vaccinology, diagnostics, and biomarker discovery using proteomic analyses. Dr. Ndao serves as the Director of the Canadian National Reference Centre for Parasitology (NRCP) and holds the following appointments: Chair of the Facility Animal Care Committee (FACC) Research Institute of the McGill University Health Centre Glen, Co-chair of the Food and Environmental Parasitology Network (Health Canada), among others. He is also a member of several boards and committees including: the World Federation of Parasitologists, the executive board of the International Federation of Tropical Medicine, and the Scientific Committee of Pasteur Institute, to name a few.

Information & Contributors

Information

Published In

cover image Clinical Microbiology Reviews
Clinical Microbiology Reviews
Volume 37Number 114 March 2024
eLocator: e00098-23
Editor: Louisa A. Messenger, University of Nevada Las Vegas, Las Vegas, Nevada, USA
PubMed: 38319102

History

Published online: 6 February 2024

Permissions

Request permissions for this article.

Keywords

  1. Schistosoma
  2. co-infection
  3. immunology
  4. soil-transmitted helminths
  5. Plasmodium
  6. Leishmania
  7. Toxoplasma
  8. Trypanosoma
  9. intestinal protozoa
  10. Mycobacterium
  11. Salmonella
  12. UTI-causing agents
  13. SARS-CoV-2
  14. HIV
  15. cytomegalovirus
  16. hepatitis
  17. arboviruses

Contributors

Authors

Division of Experimental Medicine, McGill University, Montreal, Canada
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Canada
Author Contributions: Conceptualization, Writing – original draft, and Writing – review and editing.
Division of Experimental Medicine, McGill University, Montreal, Canada
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Canada
Author Contributions: Writing – original draft and Writing – review and editing.
Department of Microbiology and Immunology, McGill University, Montreal, Canada
Author Contributions: Writing – original draft and Writing – review and editing.
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Canada
Department of Microbiology and Immunology, McGill University, Montreal, Canada
Author Contributions: Writing – original draft and Writing – review and editing.
Division of Experimental Medicine, McGill University, Montreal, Canada
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Canada
Department of Microbiology and Immunology, McGill University, Montreal, Canada
National Reference Centre for Parasitology, Research Institute of the McGill University Health Centre, Montreal, Canada
Author Contributions: Resources, Supervision, and Writing – review and editing.

Editor

Louisa A. Messenger
Editor
University of Nevada Las Vegas, Las Vegas, Nevada, USA

Notes

The authors declare no conflict of interest.

Metrics & Citations

Metrics

Note:

  • For recently published articles, the TOTAL download count will appear as zero until a new month starts.
  • There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.
  • Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

View Options

Get Access

LOGIN OPTIONS
Non-Member Login
Buy Article
Clinical Microbiology Reviews Vol.37 • Issue 1 • ASM Journals Pay Per View, PPV 25
Journal Subscription
Clinical Microbiology Reviews
ASM members can purchase subscriptions to journals.
Join or renew

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Get Access

LOGIN OPTIONS
Non-Member Login
Buy Article
Clinical Microbiology Reviews Vol.37 • Issue 1 • ASM Journals Pay Per View, PPV 25
Journal Subscription
Clinical Microbiology Reviews
ASM members can purchase subscriptions to journals.
Join or renew

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Figures and Media

Figures

Media

Tables

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy